Dolutegravir Exposure Management
Clinical Considerations
- The Centers for Disease Control and Prevention, as reported in MMWR Recommendations and Reports, recommends checking for drug interactions if the patient is taking other medications, particularly those containing polyvalent cations (aluminum, calcium, iron, magnesium) 1
Special Populations Considerations
Pregnancy
- The American College of Obstetricians and Gynecologists, as reported in JAMA, recommends that if exposure occurs in a pregnant woman, dolutegravir with TAF/FTC (or TDF/FTC if TAF/FTC is not available) is the recommended ART regimen in pregnancy 2
- The National Institutes of Health, as reported in JAMA, has shown that dolutegravir has high antiviral efficacy and low rates of adverse birth outcomes in pregnancy 2
Patients with HIV
- The Department of Health and Human Services, as reported in JAMA, recommends that for HIV-positive individuals with dolutegravir exposure, their current antiretroviral regimen should be assessed 3
- The International Antiviral Society, as reported in JAMA, recommends dolutegravir-based regimens for most people with HIV, including combinations like BIC/TAF/FTC or dolutegravir plus TXF/XTC 3